



Sample Information

Patient Name: 吳秀美
Gender: Female
ID No.: A203092192
History No.: 46229747
Age: 72

Ordering Doctor: DOC1242E 劉峻宇
Ordering REQ.: D6GE89L
Signing in Date: 2021/10/21

Path No.: S110-99819
MP No.: F21084
Assay: Oncomine Focus Assay
Sample Type: FFPE
Block No.: S110-28507A
Percentage of tumor cells: 70%

Reporting Doctor: DOC5466K 葉奕成 (Phone: 8#5466)

Note:

Sample Cancer Type: Head and Neck Cancer

Table of Contents	Page
Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)	2
Biomarker Descriptions	2
Relevant Therapy Summary	3
Relevant Therapy Details	4
Clinical Trials Summary	18
Alert Details	18

Report Highlights

1 Relevant Biomarkers
3 Therapies Available
4 Clinical Trials

Relevant Head and Neck Cancer Variants

Gene	Finding
ERBB2	None detected
NTRK1	None detected
NTRK2	None detected
NTRK3	ETV6-NTRK3 fusion

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IA	ETV6-NTRK3 fusion ETS variant transcription factor 6 - neurotrophic receptor tyrosine kinase 3 Prognostic significance: None Diagnostic significance: None	entrectinib ^{1, 2} larotrectinib ¹	entrectinib larotrectinib TRK inhibitor	4

Public data sources included in relevant therapies: FDA¹, NCCN, EMA², ESMO

Public data sources included in prognostic and diagnostic significance: NCCN, ESMO

Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

Gene Fusions (RNA)

Genes	Variant ID	Locus	Read Count
ETV6-NTRK3	ETV6-NTRK3.E4N15.COSF823.1	chr12:12006495 - chr15:88483984	421
ETV6-NTRK3	ETV6-NTRK3.E5N15.COSF571.1	chr12:12022903 - chr15:88483984	57213

Biomarker Descriptions

ETV6 (ETS variant transcription factor 6)

Background: The ETV6 gene encodes the E twenty-six (ETS) variant 1 transcription factor. ETV6 contains an N-terminal pointed (PNT) domain responsible for protein-protein interactions and a C-terminal ETS domain involved in DNA binding¹. ETV6 plays a critical role in embryonic development as well as hematopoiesis and is the target of chromosomal rearrangement and missense mutations in hematological malignancies as well as solid tumors^{2,3}. Hereditary mutations in ETV6 are associated with a predisposition to hematological cancers, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS)^{4,5,6}.

Alterations and prevalence: ETV6 translocations are prevalent in hematological malignancies and have been observed with numerous fusion partners⁷. The most recurrent translocation is t(12;21)(q34;q11) which results in ETV6-RUNX1 fusion and is observed in 20-25% childhood acute lymphoblastic leukemia (ALL)^{7,8,9}. ETV6-RUNX1 fusions are also observed in adult ALL (2%)^{8,9}. The t(5;12)(q33;p13) translocation which results in the ETV6-PDGFRB fusion is recurrent in chronic myelomonocytic leukemia (CMML)^{7,10}. Other ETV6 fusions including ETV6-PDGFRB, ETV6-NTRK2, ETV6-NTRK3, and ETV6-ABL1 are reported in hematological malignancies as well as solid tumors^{3,7,11}. ETV6 fusions involving a receptor tyrosine kinase (RTK) fusion partner retains the ETV6 PNT domain and the tyrosine kinase domain of the RTK, leading to constitutive kinase activation^{7,11}. Mutations in ETV6 are primarily missense, nonsense, or frameshift and are observed in about 1-5% of select myeloid malignancies and solid tumors, including chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), MDS, AML, ALL, melanoma, lung, bladder, stomach, colorectal, and uterine cancers^{1,12,13}. ETV6 mutations occur in the PNT and ETS domain of ETV6 and may impair ETV6 oligomerization or DNA-binding, respectively¹.

Potential relevance: ETV6-NTRK3 fusions are used as an ancillary diagnostic marker in congenital/infantile fibrosarcoma¹⁴. Nonsense or frameshift mutations in ETV6 are independently associated with poor prognosis in MDS⁶. However, ETV6-RUNX1 fusions are associated with favorable outcomes in ALL and good risk in B-cell ALL (B-ALL)⁹. ETV6 fusions that partner with a RTKs demonstrate response to various tyrosine kinase inhibitors such as imatinib, nilotinib, and entrectinib. Specifically, individual case reports of an ETV6-PDGFRB fusion chronic eosinophilic leukemia patient and an ETV6-PDGFRB fusion CMML patient treated with imatinib demonstrated complete cytogenetic response (CCyR) and complete hematological responses, respectively^{15,16}. Additionally, an ETV6-ABL1 fusion Ph-negative CML patient treated with nilotinib demonstrated CCyR and major molecular response (MMR) at 22 months from diagnosis¹⁷. In another case report, an ETV6-NTRK3 fusion mammary analogue secretory carcinoma (MASC) patient demonstrated partial response to entrectinib with 89% reduction in tumor burden¹⁸.

Biomarker Descriptions (continued)

NTRK3 (neurotrophic receptor tyrosine kinase 3)

Background: The NTRK genes encode a family of neurotrophic receptor tyrosine kinases that function as receptors for nerve growth factors. NTRKs are activated by different neurotrophins and are important for the development of the nervous system¹⁹. The NTRK1,2,3 proteins are also known as tropomyosin related kinases (TrkA,B,C) because NTRK1 was originally discovered as part of a chimeric fusion gene with tropomyosin-3 isolated from a human colon carcinoma cell line²⁰. NTRKs are the target of recurrent chromosomal rearrangements that generate fusion proteins containing the intact tyrosine kinase domain combined with numerous fusion partner genes^{21,22}. NTRK fusion kinases are constitutively active and lead to increased RAS/RAF/MEK/ERK, PI3K/AKT/MTOR, or PLCγ/PKC pathway signaling and can promote cell growth and proliferation^{21,23}.

Alterations and prevalence: NTRK fusions are infrequently observed in diverse cancer types including glioma, glioblastoma, lung adenocarcinoma, colorectal carcinoma, thyroid cancer, and sarcoma^{13,21,24,25,26}. In certain cancer subtypes, including infantile fibrosarcoma, papillary thyroid carcinoma, and secretory carcinoma of the breast or salivary gland, NTRK fusions are more prevalent^{21,27,28,29}.

Potential relevance: The first-generation selective tropomyosin receptor kinase (TRK) inhibitor, larotrectinib³⁰, is approved (2018) for the treatment of patients with any solid tumors harboring NTRK gene fusions and is the first approved small molecule inhibitor with tissue agnostic indication. Entrectinib³¹ is another first-generation TRK inhibitor approved (2019) for NTRK fusion-positive solid tumors as well as ROS1-positive non-small cell lung cancer (NSCLC). However, acquired resistance to first-generation NTRK inhibition is often mediated by the acquisition of solvent-front and gatekeeper mutations in the kinase domain³². Consequently, the second generation TRK inhibitor, repotrectinib³³, was granted fast-track designation by the FDA (2020) for the treatment of patients with advanced solid tumors and an NTRK gene fusion that have progressed following treatment with at least one prior line of chemotherapy and prior TRK inhibitor treatment.

Relevant Therapy Summary

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

ETV6-NTRK3 fusion

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
entrectinib	●	◐	●	○	● (II)
larotrectinib	●	◐	×	○	● (II)
TRK inhibitor	×	×	×	○	×
repotrectinib	×	×	×	×	● (I/II)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Details

Current FDA Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

FDA information is current as of 2021-08-18. For the most up-to-date information, search www.fda.gov.

ETV6-NTRK3 fusion

● entrectinib

Cancer type: Solid Tumor

Label as of: 2019-08-15

Variant class: NTRK fusion

Indications and usage:

ROZLYTREK® is a kinase inhibitor indicated for the treatment of:

- Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
- Adult and pediatric patients 12 years of age and older with solid tumors that:
 - have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,
 - are metastatic or where surgical resection is likely to result in severe morbidity, and
 - have progressed following treatment or have no satisfactory alternative therapy

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

● larotrectinib

Cancer type: Solid Tumor

Label as of: 2021-03-25

Variant class: NTRK fusion

Indications and usage:

VITRAKVI® is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:

- have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment.

Select patients for therapy based on an FDA-approved test.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210861s006lbl.pdf

Current NCCN Information

- ☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

NCCN information is current as of 2021-08-02. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

ETV6-NTRK3 fusion

● entrectinib

Cancer type: Solid Tumor

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Brain Metastases (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 1.2021]

● entrectinib

Cancer type: Head and Neck Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Salivary Gland Neoplasm; Recurrent, Unresectable, Distant Metastases (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Head and Neck Cancers [Version 3.2021]

● larotrectinib

Cancer type: Solid Tumor

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Brain Metastases (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 1.2021]

● larotrectinib

Cancer type: Head and Neck Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Salivary Gland Neoplasm; Recurrent, Unresectable, Distant Metastases (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Head and Neck Cancers [Version 3.2021]

ETV6-NTRK3 fusion (continued)

○ entrectinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: NTRK3 fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic (First-line therapy); Preferred intervention
- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic (Subsequent therapy)
- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic, Progression (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2021]

○ larotrectinib

Cancer type: Non-Small Cell Lung Cancer

Variant class: NTRK3 fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic (First-line therapy); Preferred intervention
- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic (Subsequent therapy)
- Adenocarcinoma, Large Cell, Squamous Cell, Not otherwise specified (NOS); Advanced, Metastatic, Progression (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 5.2021]

○ entrectinib

Cancer type: Breast Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Stage IV; Recurrent, Invasive, Unresectable, Local (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Breast Cancer [Version 5.2021]

○ entrectinib

Cancer type: Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Glioblastoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Recurrent (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 1.2021]

ETV6-NTRK3 fusion (continued)

○ entrectinib

Cancer type: Ganglioglioma, Pilocytic Astrocytoma, Variant class: NTRK fusion
Pleomorphic Xanthoastrocytoma, Subependymal
Giant Cell Astrocytoma

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- WHO CNS Tumor Grade I, WHO CNS Tumor Grade II; Recurrent, Progression (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 1.2021]

○ entrectinib

Cancer type: Colorectal Cancer Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 2.2021]

○ entrectinib

Cancer type: Cutaneous Melanoma Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic, Unresectable, Progression (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 2.2021]

○ entrectinib

Cancer type: Esophageal Cancer, Variant class: NTRK fusion
Gastroesophageal Junction Adenocarcinoma

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Squamous Cell; Unresectable, Locally Advanced, Recurrent, Metastatic (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Esophageal and Esophagogastric Junction Cancers [Version 3.2021]

ETV6-NTRK3 fusion (continued)

○ entrectinib

Cancer type: Gastric Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Locally Advanced, Recurrent, Metastatic (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Gastric Cancer [Version 3.2021]

○ entrectinib

Cancer type: Gastrointestinal Stromal Tumor

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Gastrointestinal Stromal Tumor [Version 1.2021]

○ entrectinib

Cancer type: Hepatocellular Carcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 3.2021]

○ entrectinib

Cancer type: Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Metastatic (First-line therapy); Useful in certain circumstances
- Unresectable, Metastatic, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 3.2021]

ETV6-NTRK3 fusion (continued)

○ entrectinib

Cancer type: Ovarian Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Epithelial, Less Common Ovarian Cancers, Fallopian Tube, Primary Peritoneal; Recurrent (Recurrence therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Ovarian Cancer [Version 1.2021]

○ entrectinib

Cancer type: Pancreatic Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma; Locally Advanced, Metastatic, Recurrent (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Pancreatic Adenocarcinoma [Version 2.2021]

○ entrectinib

Cancer type: Colorectal Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 1.2021]

○ entrectinib

Cancer type: Soft Tissue Sarcoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unspecified histology; Advanced, Metastatic (First-line therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 2.2021]

ETV6-NTRK3 fusion (continued)

○ entrectinib

Cancer type: Thyroid Gland Follicular Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Thyroid Gland Papillary Carcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Locally Recurrent, Advanced, Metastatic (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 1.2021]

○ entrectinib

Cancer type: Thyroid Gland Anaplastic Carcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Stage IVA, Stage IVB; Local, Unresectable (Neoadjuvant therapy)
- Stage IVC; Metastatic (Second-line therapy); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 1.2021]

○ larotrectinib

Cancer type: Breast Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Stage IV; Recurrent, Invasive, Unresectable, Local (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Breast Cancer [Version 5.2021]

○ larotrectinib

Cancer type: Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Glioblastoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Recurrent (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 1.2021]

ETV6-NTRK3 fusion (continued)

○ larotrectinib

Cancer type: Ganglioglioma, Pilocytic Astrocytoma, Variant class: NTRK fusion
Pleomorphic Xanthoastrocytoma, Subependymal
Giant Cell Astrocytoma

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- WHO CNS Tumor Grade I, WHO CNS Tumor Grade II; Recurrent, Progression (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Central Nervous System Cancers [Version 1.2021]

○ larotrectinib

Cancer type: Colorectal Cancer **Variant class:** NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 2.2021]

○ larotrectinib

Cancer type: Cutaneous Melanoma **Variant class:** NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic, Unresectable, Progression (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Cutaneous Melanoma [Version 2.2021]

○ larotrectinib

Cancer type: Esophageal Cancer, **Variant class:** NTRK fusion
Gastroesophageal Junction Adenocarcinoma

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Squamous Cell; Unresectable, Locally Advanced, Recurrent, Metastatic (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Esophageal and Esophagogastric Junction Cancers [Version 3.2021]

ETV6-NTRK3 fusion (continued)

○ larotrectinib

Cancer type: Gastric Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Locally Advanced, Recurrent, Metastatic (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Gastric Cancer [Version 3.2021]

○ larotrectinib

Cancer type: Gastrointestinal Stromal Tumor

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Gastrointestinal Stromal Tumor [Version 1.2021]

○ larotrectinib

Cancer type: Hepatocellular Carcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 3.2021]

○ larotrectinib

Cancer type: Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Metastatic (First-line therapy); Useful in certain circumstances
- Unresectable, Metastatic, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 3.2021]

ETV6-NTRK3 fusion (continued)

○ larotrectinib

Cancer type: Ovarian Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Epithelial, Less Common Ovarian Cancers, Fallopian Tube, Primary Peritoneal; Recurrent (Recurrence therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Ovarian Cancer [Version 1.2021]

○ larotrectinib

Cancer type: Pancreatic Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma; Metastatic (First-line therapy); Useful in certain circumstances
- Adenocarcinoma; Locally Advanced, Metastatic, Recurrent (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Pancreatic Adenocarcinoma [Version 2.2021]

○ larotrectinib

Cancer type: Colorectal Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Metastatic (Subsequent therapy)

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 1.2021]

○ larotrectinib

Cancer type: Soft Tissue Sarcoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unspecified histology; Advanced, Metastatic (First-line therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 2.2021]

ETV6-NTRK3 fusion (continued)

○ larotrectinib

Cancer type: Thyroid Gland Follicular Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Thyroid Gland Papillary Carcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Locally Recurrent, Advanced, Metastatic (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 1.2021]

○ larotrectinib

Cancer type: Thyroid Gland Anaplastic Carcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Stage IVA, Stage IVB; Local, Unresectable (Neoadjuvant therapy)
- Stage IVC; Metastatic (Second-line therapy); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 1.2021]

○ entrectinib

Cancer type: Cervical Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Recurrent, Metastatic (Second-line therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Cervical Cancer [Version 1.2021]

○ entrectinib

Cancer type: Pancreatic Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Adenocarcinoma; Metastatic (First-line therapy); Useful in certain circumstances
- Adenocarcinoma; Locally Advanced, Metastatic, Recurrent (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Pancreatic Adenocarcinoma [Version 2.2021]

ETV6-NTRK3 fusion (continued)

○ entrectinib

Cancer type: Endometrial Carcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Advanced, Recurrent (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 3.2021]

○ entrectinib

Cancer type: Uterine Sarcoma

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Recurrent, Metastatic, Progression (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 3.2021]

○ larotrectinib

Cancer type: Cervical Cancer

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Recurrent, Metastatic (Second-line therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Cervical Cancer [Version 1.2021]

○ larotrectinib

Cancer type: Endometrial Carcinoma

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Advanced, Recurrent (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 3.2021]

○ larotrectinib

Cancer type: Uterine Sarcoma

Variant class: NTRK fusion

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Recurrent, Metastatic, Progression (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 3.2021]

Current EMA Information

☒ In this cancer type ☐ In other cancer type ☐ In this cancer type and other cancer types

EMA information is current as of 2021-08-18. For the most up-to-date information, search www.ema.europa.eu/ema.

ETV6-NTRK3 fusion

☒ entrectinib

Cancer type: Solid Tumor

Label as of: 2020-10-27

Variant class: NTRK fusion

Reference:

https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf

Current ESMO Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

ESMO information is current as of 2021-08-02. For the most up-to-date information, search www.esmo.org.

ETV6-NTRK3 fusion

☐ TRK inhibitor

Cancer type: Breast Cancer

Variant class: NTRK fusion

ESMO Level of Evidence/Grade of Recommendation: I / B

Population segment (Line of therapy):

- Advanced (Line of therapy not specified)

Reference: ESMO Clinical Practice Guidelines - ESMO-ESO-ESMO Advanced Breast Cancer [Annals of Oncology (2020), doi: <https://doi.org/10.1016/j.annonc.2020.09.010> (ABC 5)]

☐ entrectinib

Cancer type: Soft Tissue Sarcoma

Variant class: NTRK fusion

ESMO Level of Evidence/Grade of Recommendation: III / A

Population segment (Line of therapy):

- Locally Advanced, Metastatic (Line of therapy not specified); ESMO-MCBS v1.1 score: 3

Reference: ESMO Clinical Practice Guidelines - ESMO-EUROCAN-Soft Tissue and Visceral Sarcomas [Ann Oncol (2021), <https://doi.org/10.1016/j.annonc.2021.07.006>]

☐ larotrectinib

Cancer type: Soft Tissue Sarcoma

Variant class: NTRK fusion

ESMO Level of Evidence/Grade of Recommendation: III / A

Population segment (Line of therapy):

- Locally Advanced, Metastatic (Line of therapy not specified); ESMO-MCBS v1.1 score: 3

Reference: ESMO Clinical Practice Guidelines - ESMO-EUROCAN-Soft Tissue and Visceral Sarcomas [Ann Oncol (2021), <https://doi.org/10.1016/j.annonc.2021.07.006>]

Clinical Trials in Taiwan region:

Clinical Trials Summary

ETV6-NTRK3 fusion

NCT ID	Title	Phase
NCT02576431	A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors	II
NCT02568267	An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements. Studies of Tumor Alterations Responsive to Targeting Receptor Kinases (STARTRK-2)	II
NCT04589845	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	II
NCT03093116	A Phase I/II, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	I/II

Alerts Informed By Public Data Sources

Current FDA Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

FDA information is current as of 2021-08-18. For the most up-to-date information, search www.fda.gov.

ETV6-NTRK3 fusion

repotrectinib

Cancer type: Solid Tumor

Variant class: NTRK fusion

Supporting Statement:

The FDA has granted Fast Track Designation to the ALK/ROS1/TRK inhibitor, repotrectinib, for:

- ROS1-positive advanced non-small cell lung cancer (NSCLC) previously treated with one prior platinum chemotherapy and one prior ROS1 TKI.
- ROS1-positive advanced non-small cell lung cancer (NSCLC) without prior ROS1 TKI treatment.
- NTRK fusion positive advanced solid tumors that have progressed following treatment with at least one prior line of chemotherapy and one or two prior TRK TKIs.

Reference:

<https://ir.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-granted-fast-track-designation>

Current NCCN Information

 Contraindicated  Not recommended  Resistance  Breakthrough  Fast Track

NCCN information is current as of 2021-08-02. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

ETV6-NTRK3 fusion

larotrectinib

Cancer type: Angiosarcoma, Pleomorphic
Rhabdomyosarcoma

Variant class: NTRK fusion

Summary:

NCCN Guidelines® include the following supporting statement(s):

- "Not recommended for angiosarcoma or pleomorphic rhabdomyosarcoma."

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 2.2021]

Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:

References

1. Wang et al. ETV6 mutation in a cohort of 970 patients with hematologic malignancies. *Haematologica*. 2014 Oct;99(10):e176-8. PMID: 24997145
2. Wang et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. *Genes Dev*. 1998 Aug 1;12(15):2392-402. PMID: 9694803
3. Huret et al. Atlas of genetics and cytogenetics in oncology and haematology in 2013. *Nucleic Acids Res*. 2013 Jan;41(Database issue):D920-4. PMID: 23161685
4. Feurstein et al. Germline ETV6 mutations and predisposition to hematological malignancies. *Int. J. Hematol*. 2017 Aug;106(2):189-195. PMID: 28555414
5. Melazzini et al. Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia. *Haematologica*. 2016 Nov;101(11):1333-1342. PMID: 27365488
6. NCCN Guidelines® - NCCN-Myelodysplastic Syndromes [Version 3.2021]
7. De et al. ETV6 fusion genes in hematological malignancies: a review. *Leuk. Res*. 2012 Aug;36(8):945-61. PMID: 22578774
8. Pui et al. Acute lymphoblastic leukemia. *N. Engl. J. Med*. 2004 Apr 8;350(15):1535-48. PMID: 15071128
9. NCCN Guidelines® - Acute Lymphoblastic Leukemia [Version 2.2019]. 2019 May 15
10. Golub et al. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. *Cell*. 1994 Apr 22;77(2):307-16. PMID: 8168137
11. Taylor et al. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. *J. Clin. Invest*. 2018 Aug 31;128(9):3819-3825. PMID: 29920189
12. Bejar et al. Clinical effect of point mutations in myelodysplastic syndromes. *N. Engl. J. Med*. 2011 Jun 30;364(26):2496-506. PMID: 21714648
13. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet*. 2013 Oct;45(10):1113-20. PMID: 24071849
14. NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 2.2021]
15. Curtis et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. *Br. J. Haematol*. 2007 Jul;138(1):77-81. PMID: 17555450
16. Curtis et al. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. *Leukemia*. 2007 Aug;21(8):1839-41. Epub 2007 May 17. PMID: 17508004
17. Gancheva et al. Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review. *Mol Cytogenet*. 2013 Sep 20;6(1):39. doi: 10.1186/1755-8166-6-39. PMID: 24053143
18. Drilon et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). *Ann Oncol*. 2016 May;27(5):920-6. doi: 10.1093/annonc/mdw042. Epub 2016 Feb 15. PMID: 26884591
19. Bibel et al. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. *Genes Dev*. 2000 Dec 1;14(23):2919-37. PMID: 11114882
20. Martin-Zanca et al. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. *Nature*. 1986 Feb 27-Mar 5;319(6056):743-8. PMID: 2869410
21. Amatu et al. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. *ESMO Open*. 2016 Mar 18;1(2):e000023. eCollection 2016. PMID: 27843590
22. Lange et al. Inhibiting TRK Proteins in Clinical Cancer Therapy. *Cancers (Basel)*. 2018 Apr 4;10(4). PMID: 29617282
23. Vaishnavi et al. TRKing down an old oncogene in a new era of targeted therapy. *Cancer Discov*. 2015 Jan;5(1):25-34. PMID: 25527197
24. Kim et al. NTRK1 fusion in glioblastoma multiforme. *PLoS ONE*. 2014;9(3):e91940. PMID: 24647444
25. Gatalica et al. Molecular characterization of cancers with NTRK gene fusions. *Mod. Pathol*. 2019 Jan;32(1):147-153. PMID: 30171197
26. Vaishnavi et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. *Nat. Med*. 2013 Nov;19(11):1469-1472. PMID: 24162815
27. Rubin et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. *Am. J. Pathol*. 1998 Nov;153(5):1451-8. PMID: 9811336
28. Brzezińska et al. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. *Mutat. Res*. 2006 Jul 25;599(1-2):26-35. PMID: 16483615

References (continued)

29. Wu et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. *Nat. Genet.* 2014 May;46(5):444-450. PMID: 24705251
30. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210861s006lbl.pdf
31. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf
32. Fuse et al. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers. *Mol. Cancer Ther.* 2017 Oct;16(10):2130-2143. PMID: 28751539
33. <https://ir.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-granted-fast-track-designation>